FIRALIS S.A

Within Basel neighbourhood and at the very heart of Europe (the triple border of France, Germany and Switzerland), Firalis is a pioneering biotechnology company, active in discovery, development and qualification of biomarkers (BM). 1) BIOMARKER PRODUCTS Firalis develops BM-based diagnostic, prognostic and theranostic tools: RUO Kits (Research-Use-Only), based on validated innovative biomarkers IVD Tools (In Vitro Diagnostic), based on a combination of clinically qualified biomarkers 2) BIOMARKER R&D Development of proprietary BMs - Cardiovascular, Inflammatory, Autoimmune and Neurology Drug Safety & Drug Efficacy Patient Stratification Personalized Medicine 3) BIOMARKER-RELATED CRO SERVICES BM Discovery for laboratories, biotechs and pharmaceutical industry: -...

Biomarkers,cardiovascular biomarkers,drug-induced vascular safety,diagnostic kits,biomarker services,biomarker assay development,in-vitro diagnostics,safety biomarkers,inflammatory,prognostic kits,biomarkers testing,next generation sequencing (ngs),alzheimer,immunoassay,rheumatoid arthritis,acute myocardial infarction,olink,htg molecular diagnostics,cro,clinical research organization,illumina,next generation sequencing,ngs,qpcr,elisa,luminex,msd,protein simple,flow cytometry,assay development,clinical validation,central lab,bioanalysis,bioanalytical service,and precision medicine

Firalis s.a operates in the Biotechnology research industry.

Firalis s.a's revenue is 11m - 100m

Firalis s.a has 11 - 50 employees.